MyFinsight
Home
Blog
About
Public offering, net of
issuance costs
$414,335K
Pre-funded warrants, net of
issuance costs
$28,120K
Exercise of stock options
$243K
Net cash provided by
financing activities
$442,698K
Net increase
(decrease) in cash and cash...
$150,921K
Canceled cashflow
$291,777K
Maturities of marketable
securities
$28,311K
Accounts payable
$4,849K
Stock-based compensation
$3,516K
Prepaid expenses and
other current assets
-$1,420K
Non-cash research and
development services
$632K
Other current
liabilities and lease...
$109K
Other
-$56K
Net accretion of
discount/premium on debt...
-$2K
Net cash used in
investing activities
-$277,287K
Net cash used in
operating activities
-$14,490K
Canceled cashflow
$28,311K
Canceled cashflow
$10,584K
Purchases of marketable
securities
$305,577K
Net loss
-$23,502K
Purchase of property,
plant and equipment
$21K
Interest receivable on
marketable securities
$1,281K
Accrued expenses
-$211K
Other non-current
assets
$80K
Back
Back
Cash Flow
Veradermics, Inc (MANE)
Veradermics, Inc (MANE)
source: myfinsight.com